TNF‐mediated inflammatory disease
Tóm tắt
TNF was originally described as a circulating factor that can cause necrosis of tumours, but has since been identified as a key regulator of the inflammatory response. This review describes the known signalling pathways and cell biological effects of TNF, and our understanding of the role of TNF in human disease. TNF interacts with two different receptors, designated TNFR1 and TNFR2, which are differentially expressed on cells and tissues and initiate both distinct and overlapping signal transduction pathways. These diverse signalling cascades lead to a range of cellular responses, which include cell death, survival, differentiation, proliferation and migration. Vascular endothelial cells respond to TNF by undergoing a number of pro‐inflammatory changes, which increase leukocyte adhesion, transendothelial migration and vascular leak and promote thrombosis. The central role of TNF in inflammation has been demonstrated by the ability of agents that block the action of TNF to treat a range of inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease and psoriasis. The increased incidence of infection in patients receiving anti‐TNF treatment has highlighted the physiological role of TNF in infectious diseases. Copyright © 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Từ khóa
Tài liệu tham khảo
Robak T, 1998, The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis, Eur Cytokine Netw, 9, 145
Ledgerwood EC, 1999, Recent advances in the molecular basis of TNF signal transduction, Lab Invest, 79, 1041
Slowik MR, 1993, Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration, Am J Pathol, 143, 1724
Bradley JR, 1993, Endothelial activation by hydrogen peroxide. Selective increases of intercellular adhesion molecule‐1 and major histocompatibility complex class I, Am J Pathol, 142, 1598
Bradley JR, 1996, Prolonged cytokine exposure causes a dynamic redistribution of endothelial cell adhesion molecules to intercellular junctions, Lab Invest, 75, 463
Munro JM, 1989, Tumor necrosis factor and interferon‐g induce distinct patterns of endothelial activation and associated leukocyte accumulation in skin of Papio anubis, Am J Pathol, 135, 121
Rollins BJ, 1990, Cytokine‐activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP‐1/JE, Am J Pathol, 136, 1229
Mark KS, 2001, Tumor necrosis factor‐alpha induces cyclooxygenase‐2 expression and prostaglandin release in brain microvessel endothelial cells, J Pharmacol Exp Therap, 297, 1051
Rudin W, 1997, Resistance to cerebral malaria in tumor necrosis factor‐alpha/beta‐deficient mice is associated with a reduction of intercellular adhesion molecule‐1 up‐regulation and T helper type 1 response, Am J Pathol, 150, 257
Kwiatkowski D, 1993, Anti‐TNF therapy inhibits fever in cerebral malaria, Qu J Med, 86, 91
Butler DM, 1995, Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNFα antibody with the interleukin‐1 receptor antagonist, Eur Cytokine Netw, 6, 225
Piguet PF, 1992, Evolution of collagen arthritis in mice is arrested by treatment with anti‐tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor, Immunology, 77, 510
Akobeng AK, Tumor necrosis factor‐alpha antibody for induction of remission in Crohn's disease, Cochrane Database Syst Rev
Lawson MM, Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis, Cochrane Database Syst Reviews
Lange U, 2000, Correlation between plasma TNFα, IGF‐1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis, Eur J Med Res, 5, 507
Inman RD, 2006, Etanercept in adult patients with early onset ankylosing spondylitis, J Rheumatol, 33, 1634
Baraliakos X, 2007, Safety and efficacy of readministration of infliximab after long‐term continuous therapy and withdrawal in patients with ankylosing spondylitis, J Rheumatol, 34, 510
Genovese MC, 2007, Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy, J Rheumatol, 34, 1040
Feuerstein GZ, 1994, Cytokines, inflammation, and brain injury: role of tumor necrosis factor‐alpha, Cerebrovasc Brain Metab Rev, 6, 341
TNF neutralization in MS: results of a randomized, placebo‐controlled multicenter study, 1999, The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, Neurology, 53, 457
Khanna D, 2003, Etanercept ameliorates sarcoidosis arthritis and skin disease, J Rheumatol, 30, 1864